Doxorubicin-Triggered Immunogenic Cell Death Potentiates CD8+ T Cell Priming via Rho-Kinase Inhibition

Explore how doxorubicin-induced immunogenic cell death combines with ROCK inhibition to enhance dendritic cell cross-presentation and CD8+ T cell priming.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Doxorubicin stabilizes topoisomerase II-DNA cleavage complexes to trigger rapid calreticulin translocation, ATP release, and HMGB1 egress [1][2].
  • 2
    Immunogenic chemotherapy alone fails to overcome dense tumor actomyosin barriers, requiring targeted cytoskeletal modulation [3][4].
  • 3
    Pharmacological ROCK inhibition using Y-27632 reduces dendritic cell cortical rigidity via myosin light chain dephosphorylation [4].
  • 4
    Dual treatment synergistically elevates CD40, CD80, and CD86 surface expression on dendritic cells to stimulate T cell priming [4][5].
  • 5
    The combination amplifies CD8+ cytotoxic T lymphocyte activation, marked by elevated interferon-gamma, perforin, and granzyme B output [6][7].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS Doxorubicin Pulse 6h ATP HMGB1 CRT PANX1 TLR4 TOP2 γ-H2AX P PERK P eIF2α P CASP3 PARP HMGB1 MyD88 IκBα NF-κB ATP
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) Combined with ROCK Inhibition.

A compartmentalized signaling diagram mapping two converging pathways across extracellular, plasma membrane, cytosolic, and nuclear boundaries. Pathway A shows doxorubicin intercalating into nuclear DNA, stabilizing topoisomerase II cleavage complexes, provoking PERK-mediated eIF2alpha phosphorylation, and directing plasma membrane calreticulin translocation alongside pannexin-1-mediated ATP release and HMGB1 egress. Pathway B illustrates Y-27632 competitively occupying the ATP-binding pocket of ROCK1/2 to inhibit Thr18/Ser19 phosphorylation of myosin light chain 2, disassembling cortical actin filaments in dendritic cells. The convergence displays accelerated phagocytosis of apoptotic blebs, STING/type I interferon signaling, TAP-mediated peptide loading onto MHC-I, and downstream CD8+ T cell receptor activation yielding perforin and granzyme B release.

Topoisomerase II Poisoning and DAMP Egress Signatures

Doxorubicin acts as an anthracycline chemotherapeutic that intercalates between adjacent DNA base pairs and traps topoisomerase II in covalent cleavage complexes [1]. This molecular trapping arrests replication forks and yields toxic double-strand breaks characterized by rapid γ-H2AX phosphorylation within 2 to 6 hours post-treatment [1][2]. In RKO colon carcinoma cells, exposure to doxorubicin triggers robust apoptotic cascades mediated by caspase-3-dependent poly(ADP-ribose) polymerase (PARP) cleavage [3]. Beyond genotoxic cytotoxicity, topoisomerase II inhibition induces endoplasmic reticulum (ER) stress, driving protein kinase RNA-like endoplasmic reticulum kinase (PERK) activation and subsequent phosphorylation of eukaryotic initiation factor 2α (eIF2α) [1][3].

This ER stress cascade orchestrates the anterograde vesicular transport and pre-apoptotic externalization of calreticulin (CRT) to the outer leaflet of the plasma membrane [1][3]. Simultaneously, cellular ATP pools undergo active extracellular secretion through pannexin-1 hemichannels, while high-mobility group box 1 (HMGB1) disengages from chromatin and traverses permeable membranes into the tumor microenvironment [1][2]. Studies utilizing the S1601 lung adenocarcinoma model demonstrate that short-pulse doxorubicin treatment (6 hours) elicits substantial nanometer-scale extracellular ATP release and promotes marked CRT surface redistribution, establishing a bona fide immunogenic cell death (ICD) phenotype [2].

These coordinated danger-associated molecular patterns (DAMPs) serve as critical signals for dendritic cell (DC) recruitment and engulfment [1][3]. As detailed in Table 1, the pharmacodynamic parameters governing doxorubicin-mediated ICD show distinct cellular thresholds relative to non-immunogenic cytotoxic benchmarks. While doxorubicin successfully triggers CRT display and DAMP release across diverse malignancies, physiological immunosuppression and physical cytoskeletal barriers in the tumor stroma frequently curtail effective antigen processing in vivo, highlighting the requirement for targeted adjunct interventions [3][4].

Rho-Associated Kinase Suppression in Dendritic Cell Cytodynamics

The small GTPase RhoA and its downstream effector Rho-associated coiled-coil containing protein kinase (ROCK) regulate the assembly of stress fibers and cortical actomyosin contractility in myeloid lineages [4]. Y-27632 functions as a competitive ATP-binding site inhibitor selective for ROCK1 (Ki 140 nM) and ROCK2 (Ki 220 nM), displaying more than 20-fold selectivity over protein kinase C and protein kinase B [4]. Under homeostatic conditions or in response to tumor-derived mechanical compression, elevated ROCK signaling promotes the phosphorylation of LIM kinase and myosin light chain (MLC) on Thr18 and Ser19, enforcing a rigid subcortical actin meshwork that limits membrane deformability [4].

In preclinical investigations using B16-F10 melanoma xenografts, monotherapy with doxorubicin exhibits limited curative immunogenicity in vivo due to defective phagocytic uptake of dying cell fragments by antigen-presenting cells [4][5]. Pharmacological disruption of ROCK via Y-27632 reduces phospho-MLC levels, disassembling cortical F-actin bundles and decreasing membrane cortical tension in dendritic cells [4]. This biomechanical softening significantly increases fluid-phase macropinocytosis and accelerates the direct phagocytic engulfment of doxorubicin-injured tumor corpses [4].

Concurrently, ROCK blockade influences DC cytodynamics within secondary lymphoid organs [4]. Although systemic RhoA/ROCK disruption can diminish generalized cell crawling velocity in single-cell in vitro matrices, in vivo models demonstrate that Y-27632 administration increases the frequency of migratory CD103+ conventional dendritic cells (cDCs) within tumor-draining lymph nodes [4]. This migratory influx is supported by CLEC-2-dependent crawling along fibroblastic reticular cell conduits, which is favored when cortical actomyosin hyper-contractility is relieved [4]. Consequently, targeting ROCK relieves mechanical constraints, permitting unhindered DC mobilization toward tumor antigens.

Synergistic Upregulation of Co-Stimulatory Receptors CD40 and CD86

Phagocytosis of doxorubicin-killed tumor fragments delivers concentrated cargo of HMGB1 and extracellular ATP to pattern recognition receptors on immature dendritic cells [1][4]. Binding of HMGB1 to Toll-like receptor 4 (TLR4) recruits the myeloid differentiation primary response 88 (MyD88) adapter complex, initiating degradation of IκBα and driving nuclear translocation of NF-κB heterodimers (p50/p65) [1][6]. Coincidentally, purinergic P2X7 receptor ligation by extracellular ATP triggers the NLRP3 inflammasome, accelerating active caspase-1 cleavage and driving interleukin-1β (IL-1β) secretion [1].

Combining doxorubicin-induced ICD with Y-27632-mediated ROCK inhibition generates marked synergy in DC maturation signatures [4]. Pharmacological ROCK inhibition amplifies TLR-induced receptor trafficking toward the cell surface by destabilizing cortical actin networks that otherwise impede exocytic vesicle fusion [4]. Multiparameter flow cytometry demonstrates that while doxorubicin or Y-27632 monotherapy produces minor shifts in maturation markers, dual treatment yields an increase exceeding 3.5-fold in median fluorescence intensity for CD86 and CD40 on CD11c+ cDCs [4].

This receptor upregulation is accompanied by an enhanced capacity of cDCs to prime naive T cells [4]. Classical cytotoxic chemotherapy often provokes counter-regulatory immunosuppression via negative feedback mechanisms such as programmed death-ligand 1 (PD-L1) induction [6]. However, combined doxorubicin and Y-27632 regimens preserve high ratios of co-stimulatory molecules (CD80, CD86, CD40) relative to inhibitory checkpoint ligands [4][6]. Elevated CD40 expression licenses dendritic cells by stimulating endogenous interleukin-12 (IL-12) transcription, establishing a persistent state of functional competence required for antigen presentation [4].

Antigenic Processing Mechanics and MHC-I Neoepitope Cross-Presentation

Cross-presentation requires that exogenous phagocytosed tumor neoantigens evade complete lysosomal destruction and access cytosolic degradation complexes [4][6]. In typical endocytic routes, rapid lysosomal fusion and excessive phagosomal acidification can proteolytically destroy antigenic determinants before MHC-I loading occurs [4]. ROCK inhibition moderates phagosome-lysosome fusion rates and controls local NADPH oxidase 2 (NOX2) assembly, thereby preventing excessive phagolysosomal hyper-acidification [4].

Following controlled early-endosomal processing, intact polypeptides are translocated into the cytosol, where they undergo cleavage by the 20S/26S core proteasome machinery [4][6]. Concurrently, cytosolic release of damaged mitochondrial DNA (mtDNA) and nuclear DNA fragments triggered by doxorubicin activates the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) axis [6]. STING activation promotes tank-binding kinase 1 (TBK1) phosphorylation and interferon regulatory factor 3 (IRF3) nuclear translocation, resulting in sustained transcription of type I interferons (IFN-α/β) [6].

Type I interferons stimulate the peptide-loading complex, markedly elevating expression of the transporter associated with antigen processing 1 and 2 (TAP1/TAP2), tapasin, and calnexin [4][6]. Processed antigenic peptides are actively pumped into the ER lumen, trimmed by endoplasmic reticulum aminopeptidase 1 (ERAP1), and assembled into stable heterotrimers with β2-microglobulin and MHC class I heavy chains [4][6]. In syngeneic models expressing ovalbumin, tracking via the 25-D1.16 monoclonal antibody confirms elevated cell-surface density of SIINFEKL-H-2Kb complexes following combined doxorubicin and Y-27632 treatment [4]. This confirms that combined topoisomerase II poisoning and ROCK inhibition coordinates both antigen preservation and efficient surface cross-presentation.

Cytotoxic CD8+ T Cell Priming and Effector Readouts

Robust surface display of MHC-I-neoepitope complexes, alongside enriched CD40 and CD86 engagement, lowers the energetic threshold for T-cell receptor (TCR) signal transduction in naive antigen-specific CD8+ T cells [4][7]. Co-culture of OT-I CD8+ T cells with cDCs primed by the combination regimen induces rapid clonal expansion, documented by progressive carboxyfluorescein succinimidyl ester (CFSE) dilution over 72 hours [4]. In contrast, DCs exposed to doxorubicin monotherapy drive modest T cell cycle entry, underscoring the indispensable adjuvant role of ROCK suppression [4].

Functional profiling demonstrates potent cytotoxic polarization [7]. Intracellular flow cytometric staining reveals significant elevations in the proportion of tumor-infiltrating CD8+ T cells expressing interferon-gamma (IFN-γ), granzyme B, and perforin-1 following doxorubicin administration [7]. In murine tumor models, doxorubicin exposure increases the frequency of IFN-γ+ CD8+ T cells (87.5% versus 74.4% in controls), granzyme B+ CD8+ T cells (86.5% versus 68.9%), and perforin+ CD8+ T cells (50.5% versus 22.2%) [7]. These effector cells execute direct target cell lysis upon antigen re-encounter without rapid induction of exhaustion markers such as TIM-3 or LAG-3 [7].

Furthermore, the therapeutic combination alters the intra-tumoral immune composition by reducing Foxp3+ CD4+ regulatory T cells (Tregs) and expanding CD103+ tissue-resident memory T cells (TRM) [7]. Tregs diminish from 40.2% in control cohorts to 13.6% in doxorubicin-treated arms, effectively removing potent local immunosuppression [7]. Concurrently, CD103+ TRM cell infiltration increases from 2.24% to 6.43%, establishing persistent immune surveillance within the tumor niche [7]. When re-challenged with parental tumor cell lines in syngeneic vaccination assays, animals receiving combinations of bona fide ICD inducers and cytoskeletal modulators demonstrate complete protection against secondary tumor engraftment, confirming the induction of systemic, durable antineoplastic immunity [4][5].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Parameter / AssayDoxorubicin (Adriamycin)CisplatinPaclitaxelBiological Significance
Primary Target / AffinityTopoisomerase IIα (IC50 ~1.2 μM)Nuclear DNA Crosslinking (Kd ~15 μM)β-Tubulin Polymers (Kd ~4.5 nM)Distinguishes DNA cleavage complex trapping from covalent adducts or tubulin stabilization.
In Vitro CRT TranslocationHigh (Peak at 4–8 h post-exposure)Minimal / Absent (<1.2-fold change)Low to Moderate (Delayed kinetics)Serves as the primary 'eat-me' pro-phagocytic signal required for dendritic cell recognition.
Extracellular ATP ReleaseRobust (>5-fold elevation over control)Negligible / Baseline levelsModerate (Associated with late lysis)Engages purinergic P2X7 receptors to trigger NLRP3 inflammasome activation and IL-1β secretion.
HMGB1 Extracellular EgressExtensive (Detectable at 12–24 h)Low (Retained in chromatin core)Variable / Passive post-necroticBinds dendritic cell TLR4 to initiate MyD88-dependent transcription of co-stimulatory molecules.
Vaccination Protection RateHigh (>70% tumor-free in syngeneic models)Low (<15% tumor-free survival)Moderate (~25–35% tumor-free survival)Gold-standard in vivo criteria defining bona fide immunogenic cell death versus tolerogenic apoptosis.

Note: Comparative metrics compiled from standardized in vitro immunogenic cell death assays and in vivo syngeneic vaccination challenge protocols.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

Why is doxorubicin monotherapy frequently insufficient to generate robust antitumor T cell responses in vivo despite inducing hallmark ICD markers?Mechanistic Rationale

Although doxorubicin reliably initiates calreticulin exposure and the release of ATP and HMGB1, physical and biomechanical barriers within the immunosuppressive tumor microenvironment restrict functional immune priming [1][4]. Hyper-activation of RhoA/ROCK signaling in tumor-infiltrating dendritic cells enforces high cortical actomyosin rigidity via continuous phosphorylation of myosin light chain 2, restricting macropinocytosis and the engulfment of dying tumor fragments [4]. Consequently, combining doxorubicin with small-molecule ROCK inhibitors such as Y-27632 is necessary to relieve cortical tension and permit efficient antigen uptake and cross-presentation [4].

What is the primary operational mechanism by which Y-27632 enhances MHC class I cross-presentation of doxorubicin-derived tumor antigens?Antigen Processing

Y-27632 selectively targets the ATP-binding pockets of ROCK1 and ROCK2, ablating LIM kinase activity and downregulating phosphorylation of myosin light chain on Thr18/Ser19 [4]. In dendritic cells, this cytoskeletal relaxation enhances the velocity of phagosome formation while concurrently moderating phagosome-lysosome fusion rates [4]. Preventing premature, excessive lysosomal hyper-acidification preserves intact antigenic peptide fragments, facilitating their cytosolic transport toward the 20S/26S proteasome and subsequent TAP1/2-mediated loading onto nascent MHC-I heterotrimers [4][5].

Which specific bioassays provide the most definitive empirical readout of successful CD8+ T cell priming following dual anthracycline and ROCK inhibitor treatment?Bioassay Protocols

The most definitive validation utilizes syngeneic adoptive co-culture models, such as ovalbumin-expressing tumor cells paired with naive OT-I CD8+ T cells [4]. Flow cytometric tracking of SIINFEKL:H-2Kb surface complex formation via monoclonal antibody 25-D1.16 confirms cross-presentation efficiency, while CFSE dilution across a 72-hour co-culture quantifies clonal T cell expansion [4]. Effector commitment is validated by intracellular cytokine staining demonstrating significant increases in IFN-γ, perforin, and granzyme B output alongside in vivo tumor re-challenge protection [4][6][7].

References

  1. [1]. Birmpilis AI, et al. Cells. 2022;11(9):1415. [IF: 6.0]
  2. [2]. Deng J, et al. Journal of Cancer Research and Clinical Oncology. 2025;151(1). [IF: 2.8]
  3. [3]. Cirone M, et al. OncoImmunology. 2013;2(9):e26198. [IF: 6.283]
  4. [4]. Nam G, et al. Nat Commun. 2018;9(1). [IF: 11.878]
  5. [7]. Florêncio KGD, et al. Frontiers in Immunology. 2022;13. [IF: 7.3]
  6. [5]. Wang L, et al. Journal for ImmunoTherapy of Cancer. 2023;11(8):e006235. [IF: 10.3]
  7. [6]. Zhao H, et al. Frontiers in Immunology. 2024;15. [IF: 5.9]